Test Price
2,800 AED✅ Home Collection Available
TTN Gene Hereditary Myopathy with Early Respiratory Failure Genetic Test | 2800 AED | DHA Licensed Molecular Diagnostic
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited next‑generation sequencing (NGS) processing at DNA Labs UAE, DHA Facility License 1143. Premium Logistics: VIP mobile phlebotomy and temperature‑controlled cold‑chain home collection available daily across all UAE emirates from 8 AM to 11 PM. Clinical Guidance: Post‑test telephonic interpretation by a board‑certified consultant medical geneticist. Insurance: Direct billing verification via WhatsApp +971 54 548 8731. Turnaround Time: 3–4 weeks with structured clinical annotation.
Test Overview & Methodology
The TTN gene NGS test analyzes the entire coding region and exon‑intron boundaries of the titin gene (TTN) using high‑depth next‑generation sequencing (≥100× coverage) to identify pathogenic and likely pathogenic variants associated with hereditary myopathy with early respiratory failure (HMERF). This assay is indicated for individuals presenting with proximal or distal muscle weakness, unexplained respiratory insufficiency, elevated creatine kinase, or a confirmed family history of HMERF. Results are interpreted in accordance with ACMG/AMP guidelines and correlated with clinical phenotype by a consultant medical geneticist.
| Feature | Our NGS Test (DNA Labs UAE) | Closest Alternative |
|---|---|---|
| Precision | Full‑gene high‑depth NGS (≥100× coverage), 99.9% analytical sensitivity, exon‑level CNV detection | Sanger sequencing of selected exons only, no CNV detection, limited coverage |
| Method | Next‑generation sequencing with ISO 9001:2015 certified bioinformatics pipeline, variant confirmation by Sanger when indicated | Capillary electrophoresis with non‑accredited manual analysis |
| Turnaround Time | 3–4 weeks with structured clinical annotation and genetic counsellor review | 6–8 weeks with fragmentary gene inspection and no clinical correlation |
Physician Insight & Safety Protocols
“I recognise that genetic testing for hereditary myopathy can provoke significant anxiety. A positive TTN variant does not independently determine disease severity or progression; results must be interpreted in the full context of neuromuscular examination, respiratory function studies, and family pedigree. Patients should never discontinue prescribed respiratory or cardiac medications without direct oversight from their managing specialist. Pre‑test and post‑test genetic counselling is mandatory to ensure informed decision‑making.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Safety Advisory
Critical Warning – Do Not Interrupt Prescribed Therapy
Abrupt cessation of respiratory support medications, cardiac rhythm agents, or neuromuscular therapies may precipitate acute decompensation including respiratory failure or arrhythmia. Always consult your treating physician before making any changes to your medication regimen. This genetic test result does not replace clinical judgment or emergency care.
Safety & Exclusion Criteria
- Exclusion Criteria: Patients with acute respiratory failure or hemodynamic instability requiring immediate intensive care; minors under 18 years without a legal guardian’s written informed consent per Federal Decree‑Law No. 4 of 2016 on Medical Liability; individuals who decline mandatory pre‑test genetic counselling with a licensed genetic counsellor.
- Emergency Red Flags: Sudden severe breathlessness, crushing chest pain, cyanosis, or loss of consciousness constitute medical emergencies. Call 998 or proceed to the nearest hospital emergency department immediately. This genetic test is not a substitute for acute life‑saving intervention.
Patient FAQ & Clinical Guidance
1. What does a positive TTN mutation result mean for my health?
A positive result identifies a pathogenic or likely pathogenic variant in the TTN gene, elevating the lifetime risk for hereditary myopathy with early respiratory failure (HMERF). Clinical correlation with electromyography, respiratory function tests (FVC, MIP/MEP), cardiac evaluation, and a three‑generation family pedigree is essential. Not all carriers develop severe symptoms; variable penetrance and expressivity are well documented. A consultant medical geneticist will explain the specific variant implications and recommend surveillance protocols including periodic pulmonary function assessments.
2. How is the sample collected and is home collection available?
Our DHA‑licensed mobile phlebotomy team provides safe at‑home blood draws across all UAE emirates daily from 8 AM to 11 PM. Samples are transported in ISO‑certified temperature‑controlled cold‑chain conditions to our Dubai Healthcare City laboratory. Alternatively, you may submit an extracted DNA sample or dried blood spot on an FTA card. All collection methods are supervised by registered healthcare professionals and require pre‑test genetic counselling consent.
3. Is my genetic data protected under UAE law?
Yes. Your genetic results and personal data are fully protected under Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genomic data is stored with end‑to‑end encryption on DHA‑compliant secure servers. Results are released exclusively to the ordering physician or, with your explicit written consent, directly to you via a secure patient portal. Data is never shared with third parties without individual authorisation.
4. What is the turnaround time and how will I receive results?
The standard turnaround time is 3–4 weeks from sample receipt. This includes DNA extraction, library preparation, high‑depth NGS sequencing, bioinformatic analysis, variant interpretation by a clinical molecular geneticist, and structured report generation. Results are delivered electronically to the ordering physician and can be discussed during a telephonic post‑test counselling session. Urgent cases may be expedited upon request; please contact our genetics coordinator at +971 54 548 8731.
5. Can this test be performed on an archived tissue sample or biopsy?
The preferred specimen for TTN gene NGS analysis is peripheral whole blood collected in EDTA tubes (3–5 mL). For cases where a living sample is unavailable, we offer secure medical courier solid tissue specimen retrieval of formalin‑fixed paraffin‑embedded (FFPE) tissue blocks or archived biopsy slides. Please contact our logistics team to arrange retrieval and verify specimen suitability. FFPE analysis may have reduced sensitivity due to DNA degradation and is performed on a case‑by‑case basis.
UAE Regulatory & Data Privacy Adherence
- Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL): All genetic and personal data are processed under strict encryption standards, with explicit consent obtained for collection, storage, and sharing. Data subject rights including access, rectification, and erasure are fully upheld.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: Electronic health records and genomic data transmission comply with mandated security protocols and interoperability standards.
- Federal Decree‑Law No. 4 of 2016 on Medical Liability: Pre‑test genetic counselling, informed consent, and post‑test clinical guidance are provided in accordance with UAE medical liability regulations.
- ISO 9001:2015 Certification (Cert. INT/EGQ/2509DA/3139): Accredited quality management system ensuring audited, standardised laboratory and data handling processes.
Clinical & Logistical Metadata
| Test Name | TTN Gene Hereditary Myopathy with Early Respiratory Failure (HMERF) Genetic Test – Next‑Generation Sequencing |
| Price (AED) | 2,800 AED (includes pre‑test counselling, NGS analysis, bioinformatics, clinical annotation, and post‑test telephonic guidance) |
| Turnaround Time | 3–4 weeks from sample receipt (expedited options available upon request) |
| Sample Type / Matrix | Peripheral whole blood (EDTA, 3–5 mL); alternative: extracted DNA (≥1 µg) or dried blood spot on FTA card. FFPE tissue blocks accepted on a case‑by‑case basis via secure medical courier. |
| Methodology Used | Next‑generation sequencing (NGS) with ≥100× depth, full‑gene coverage of TTN coding regions and exon‑intron boundaries; bioinformatic analysis with ACMG/AMP variant classification; Sanger confirmation for select variants. |
| ICD-10-CM Code | G71.0 (Muscular dystrophy – hereditary myopathy with early respiratory failure) |
| LOINC Code | 21678-5 (Gene mutation analysis in Blood or Tissue by Molecular genetics method) |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians